Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Treatment of Older Adults With Acute Lymphoblastic Leukemia
The purpose of this study is to determine the safety and effectiveness of a multi-drug regimen (which includes prednisone, vincristine, cytarabine, doxorubicin, 6 mercaptopurine, and methotrexate) which is considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with PEG-asparaginase and clofarabine to treat older adults with ALL. PEG-asparaginase has been used in chemotherapy treatment regimens for both children and adults with ALL. Clofarabine has been used in chemotherapy treatment regimens for children with ALL and has been shown to decrease the number of leukemia cells. Participants with leukemia that has an abnormal chromosome, called the Philadelphia chromosome, will also be given imatinib.
- This research study has stages of treatment as follows: 1) Induction 2) Consolidation 1
3) Stem cell of Bone Marrow Transplant (if the participant is eligible). If the
participant does not have a transplant: 4) CNS Therapy 5) Consolidation 2 6)
Continuation Therapy.
- During all phases of study treatment, participants will have additional tests and
procedures to monitor their health and for research purposes. These tests will include:
physical exams, blood tests, bone marrow aspirate/biopsy and EKGs and/or ECHOs.
- INDUCTION STAGE: This stage lasts for about one month. The study drugs and the way they
are administered are as follows: Prednisone orally on days 1-21 for participants less
than 60 and days 1-7 for participants 60 or greater; Vincristine intravenously on days
1, 8, 15 and 22; Doxorubicin intravenously on days 1 and 2; PEG-Asparaginase
intravenously on days 7 and 21; Cytarabine intrathecally on day 1; Methotrexate
intrathecally on day 29; Imatinib orally on days 14-29 if participant has the
Philadelphia Chromosome.
- After induction, if there is evidence of ALL in the spinal fluid, participants may need
to receive more intrathecal therapy.
- CONSOLIDATION 1 Therapy: This stage will last about one month. Participants will
receive Consolidation 1 Therapy, regardless of whether or not their ALL is in full
remission after Induction. The study drugs and the way they are administered are as
follows: Prednisone orally days 1-5; Clofarabine intravenously days 1-5;
PEG-Asparaginase intravenously days 1 and 15; Imatinib continues orally for
participants with the Philadelphia Chromosome.
- After the participants blood counts return to normal, their bone marrow will be tested.
If the bone marrow shows remission, participants will proceed to the next stage of the
study. If the bone marrow does not show remission, the participants will no longer
continue on this study.
- STEM CELL or BONE MARROW TRANSPLANTATION: The next stage is stem cell or bone marrow
transplantation if the participant is eligible. If the participant receives a stem cell
transplant, they will receive additional chemotherapy (separate from the study drugs)
followed by an infusion of stem cells. If the participant receives a bone marrow
transplant, they will have a bone marrow aspirate and biopsy 3 months after the
transplant and 12 months from the start fo the induction to monitor the status of the
ALL. If the participant receives a bone marrow or stem cell transplant, they will
continue to be a part of the study, but will not proceed with CNS Therapy,
Consolidation 2 Therapy, and Continuation Therapy.
- CENTRAL NERVOUS SYSTEM (CNS) THERAPY: CNS therapy will begin between 2 and 6 weeks
following the end of Consolidation 1. This stage will last about one month. The study
drugs and the way they are administered are as follows: vincristine intravenously on
day 1; doxorubicin intravenously on day 1; 6 mercaptopurine orally on days 1-14;
prednisone orally on days 1-5; PEG-asparaginase intravenously on days 1 and 15;
methotrexate/cytarabine/prednisone intrathecally weekly for 3 weeks; imatinib orally
continues daily if the participant has the Philadelphia Chromosome.
- Radiation therapy will also be given during this stage of the participant is under 60
years old. The purpose of radiation therapy is to prevent ALL from coming back in the
brain. Radiation will be given in 8 treatments, given once a day, and will be scheduled
with other study treatment.
- CONSOLIDATION 2 THERAPY: This stage begins as soon as CNS Therapy ends and lasts about
8 months. Participants will receive repeated cycles of the study drug treatment about
every 4 weeks. The study drugs and the way they are administered are as follows:
vincristine intravenously on day 1; doxorubicin intravenously on day 1; 6
mercaptopurine orally on days 1-14; prednisone orally days 1-5; PEG-asparaginase orally
on days 1 and 15 (first cycle only); imatinib orally continues daily if the participant
has Philadelphia chromosome.
- CONTINUATION THERAPY: This stage begins at the end of Consolidation 2 Therapy. The goal
of this stage is to get rid of all of the ALL in the body. Participants will receive
repeated cycles of the study drug treatment every 4 weeks. It will last until the
participant has been in remission for 2 years. The study drugs and the way they are
administered are as follows: vincristine intravenously on day 1; mercaptopurine orally
on days 1-14; prednisone orally on days 1-5; methotrexate intravenously on day 15;
imatinib orally continues daily if the participant has Philadelphia chromosome.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |